CD19xCD3 Bispecific Antibody Dosing for Burkitt Lymphoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Burkitt lymphoma or leukemia, such as chemotherapy regimens like R-CHOP and DHAP, often result in relapse or refractory cases, with no established standard therapy, leading to high mortality rates due to the aggressive nature and rapid progression of the disease.
Innovation Solution
A novel treatment regimen involving a CD19×CD3 bispecific antibody is administered in a specific dosing schema, where a first dose of 15 μg/m2/d is given for 4 days, followed by a second dose of 60 μg/m2/d for a period exceeding the first, with pentosane polysulfate administered prior to and during treatment cycles to manage potential neurological adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aggressive and intensive chemotherapy is used to treat Burkitt lymphoma or leukemia, then the treatment effectiveness is improved, but the toxicity and side effects increase significantly
Solution Approach 1:
The patent applies parameter changes by transitioning from conventional chemotherapy to a bispecific antibody treatment regimen with specific dosing parameters (15 μg/m2/d for 4 days followed by 60 μg/m2/d). This changes the fundamental treatment modality and dosing parameters to achieve therapeutic efficacy while reducing the severe toxicity associated with intensive chemotherapy
Solution Approach 2:
The CD19×CD3 bisspecific antibody acts as an intermediary that bridges T-cells and B-cells (targeting CD19). This mediator enables targeted immunotherapy that achieves treatment effectiveness through biological mechanisms rather than direct chemical cytotoxicity, thereby reducing the harmful side effects of conventional chemotherapy
2Ease of manufacture
If standard chemotherapy regimens are used, then initial treatment is provided, but relapse or refractory cases occur with no established standard therapy
Solution Approach 1:
The patent implements a dynamic treatment approach with a specific two-phase dosing regimen that adapts the antibody administration over time (initial lower dose followed by higher dose). This dynamic dosing strategy addresses both initial treatment needs and prevents relapse by maintaining therapeutic pressure on the disease
Solution Approach 2:
The patent applies preliminary action by administering a first dose of 15 μg/m2/d for 4 days before escalating to the second dose of 60 μg/m2/d. This preliminary lower-dose phase prepares the patient's system and reduces initial toxicity while establishing therapeutic effect, thereby improving long-term treatment success
3Reliability
If higher doses of bispecific antibody are administered, then treatment efficacy is improved, but neurological adverse effects increase
Solution Approach 1:
The patent segments the treatment into two distinct phases: a first phase with lower dose (15 μg/m2/d) for 4 days, and a second phase with higher dose (60 μg/m2/d) for extended duration. This segmentation allows the body to adapt to the therapy progressively, reducing neurological adverse effects while maintaining treatment efficacy
Solution Approach 2:
The patent employs periodic action through its structured dosing schedule with specific time intervals and dose escalations. The treatment alternates between lower and higher dose periods, creating a rhythmic therapeutic approach that maximizes efficacy while managing toxicity through periodic dose modulation
Data Source
AI summary
The present invention relates to a method of treating Burkitt lymphoma or leukemia in a patient, the method comprising administering to said patient a composition comprising a CD19×CD3 bispecific antibody in at least one treatment cycle, wherein the treatment cycle comprises administering a first dose of 15 μg/m2/d of the CD19×CD3 bispecific antibody for a first period of time of 4 days, and administering after the first dose a second dose of 60 Kg/m2/d of the CD19×CD3 bispecific antibody for a second period of time, wherein the second period of time exceeds the first period of time.